944904-60-3

Usage

Uses

Used in Organic Synthesis:
5-bromo-2-(trifluoromethyl)isonicotinaldehyde is used as a reagent in organic synthesis for its unique chemical properties. The presence of bromine and trifluoromethyl groups allows for various reactions and transformations, making it a versatile building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 5-bromo-2-(trifluoromethyl)isonicotinaldehyde is used as a building block for the synthesis of various bioactive molecules. Its unique structure and properties make it a promising candidate for the development of new drugs and pharmaceutical agents.
Used in Medicinal Chemistry:
5-bromo-2-(trifluoromethyl)isonicotinaldehyde is also used in medicinal chemistry for its potential pharmacological applications. Its versatile nature and unique chemical properties make it an interesting compound for researchers and pharmaceutical companies to explore its potential in the development of new therapeutic agents.

Upstream product

• 1432054-93-7 5-bromo-N-methoxy-N-methyl-2-(trifluoromethyl)pyridine-4-carboxamide 
• 68-12-2 N,N-dimethyl-formamide 
• 436799-32-5 5-bromo-2(trifluoromethyl)pyridine 
• 749875-16-9 5-bromo-2-(trifluoromethyl)pyridine-4-carboxylic acid 

Downstream Products

• 1375303-24-4 C₈H₂BrF₆NO 

Relevant academic research and scientific papers

Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties ()

Cholesteryl ester transfer protein (CETP) represents one of the key regulators of the homeostasis of lipid particles, including high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles. Epidemiological evidence correlates increased HDL and decreased LDL to coronary heart disease (CHD) risk reduction. This relationship is consistent with a clinical outcomes trial of a CETP inhibitor (anacetrapib) combined with standard of care (statin), which led to a 9% additional risk reduction compared to standard of care alone. We discuss here the discovery of MK-8262, a CETP inhibitor with the potential for being the best-in-class molecule. Novel in vitro and in vivo paradigms were integrated to drug discovery to guide optimization informed by a critical understanding of key clinical adverse effect profiles. We present preclinical and clinical evidence of MK-8262 safety and efficacy by means of HDL increase and LDL reduction as biomarkers for reduced CHD risk.

IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF

The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.

Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression

Embryonic ectoderm development (EED) is a promising therapeutic target for human cancers and other diseases. We report herein the discovery of exceptionally potent and efficacious EED inhibitors. By conformational restriction of a previously reported EED

COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE

The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease. The compounds are inhibitors or modulators of HIF2alpha.

NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.

FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.